RxDoctor Payments Data

Ashley Gallagher, NP

Family · Newark, DENPI 1194270678

Payments from drug & device makers

$1,023in general payments, 2019–2025

Across 44 payments — averaging $23.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$234
  • Pfizer$169
  • Kestra Medical Technology Services, Inc.$144
  • Johnson & Johnson$85
  • AstraZeneca$66
  • Boston Scientific$63
  • plus $262 from 7 others

What the payments were for

  • Food & beverage$1,023100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,023 in reported general payments places this provider in the 65th percentile of 523 family providers in Delaware.

See all family providers in Delaware

Medicare billing

Part B allowed, 2024
$46,848
Medicare patients
420
Services billed
718

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban150$177,526
XareltoRivaroxaban60$79,753
JardianceEmpagliflozin56$42,034
EntrestoSacubitril/Valsartan13$17,117
BrilintaTicagrelor21$17,098
Metoprolol Succinate380$5,851
Praluent PenAlirocumab11$5,607
Atorvastatin Calcium317$5,037
Rosuvastatin Calcium88$2,197
Isosorbide Mononitrate ErIsosorbide Mononitrate65$1,885
Carvedilol122$1,651
Valsartan33$1,596
Ezetimibe45$1,206
ClopidogrelClopidogrel Bisulfate83$1,156
Lisinopril142$929

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$169$177,526150 claims
Johnson & JohnsonXarelto$85$79,75360 claims
Boehringer IngelheimJardiance$234$42,03456 claims
NovartisEntresto$54$17,11713 claims
AstraZenecaBrilinta$66$17,09821 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 523 family providers in Delaware.

Other family in Newark

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →